$EGRX
EAGLE PHARMACEUTICALS, INC.

2023 Q3 Form 10-Q Financial Statement

#000082787123000021 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $64.65M $74.14M
YoY Change -12.8% 54.05%
Cost Of Revenue $16.86M $23.66M
YoY Change -28.76% 199.28%
Gross Profit $47.79M $50.47M
YoY Change -5.32% 25.5%
Gross Profit Margin 73.92% 68.08%
Selling, General & Admin $27.65M $36.83M
YoY Change -24.93% 121.4%
% of Gross Profit 57.86% 72.98%
Research & Development $9.833M $11.44M
YoY Change -14.02% 15.4%
% of Gross Profit 20.58% 22.66%
Depreciation & Amortization $100.0K $1.634M
YoY Change -93.88% 769.15%
% of Gross Profit 0.21% 3.24%
Operating Expenses $37.48M $48.27M
YoY Change -22.34% 81.82%
Operating Profit $10.30M $2.203M
YoY Change 367.73% -79.64%
Interest Expense $1.448M -$1.008M
YoY Change -243.65% -338.86%
% of Operating Profit 14.05% -45.76%
Other Income/Expense, Net -$1.006M -$7.063M
YoY Change -85.76% 33.97%
Pretax Income $9.298M -$5.868M
YoY Change -258.45% -205.77%
Income Tax $4.134M $3.582M
% Of Pretax Income 44.46%
Net Earnings $5.164M -$9.450M
YoY Change -154.65% -361.63%
Net Earnings / Revenue 7.99% -12.75%
Basic Earnings Per Share $0.39 -$0.74
Diluted Earnings Per Share $0.39 -$736.2K
COMMON SHARES
Basic Shares Outstanding 12.99M shares 13.09M shares 12.70M shares
Diluted Shares Outstanding 13.15M shares 12.84M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.35M $36.56M
YoY Change -58.01% -66.37%
Cash & Equivalents $15.35M $36.56M
Short-Term Investments
Other Short-Term Assets $3.820M $14.26M
YoY Change -73.22% 219.92%
Inventory $42.48M $57.71M
Prepaid Expenses
Receivables $115.1M $85.92M
Other Receivables $1.144M $0.00
Total Short-Term Assets $187.3M $194.5M
YoY Change -3.71% 10.8%
LONG-TERM ASSETS
Property, Plant & Equipment $1.013M $1.459M
YoY Change -30.57% -25.83%
Goodwill $45.03M
YoY Change
Intangibles $107.4M
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.41M $30.31M
YoY Change 10.21% 41.23%
Total Long-Term Assets $217.6M $187.3M
YoY Change 16.16% 111.07%
TOTAL ASSETS
Total Short-Term Assets $187.3M $194.5M
Total Long-Term Assets $217.6M $187.3M
Total Assets $404.8M $381.8M
YoY Change 6.04% 44.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.84M $19.97M
YoY Change -20.67% 79.34%
Accrued Expenses $61.33M $56.88M
YoY Change 7.83% 122.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $8.297M $21.84M
YoY Change -62.02% 173.04%
Total Short-Term Liabilities $86.63M $109.0M
YoY Change -20.5% 143.96%
LONG-TERM LIABILITIES
Long-Term Debt $61.90M $28.02M
YoY Change 120.92% 31.1%
Other Long-Term Liabilities $4.256M $2.256M
YoY Change 88.65% -32.86%
Total Long-Term Liabilities $66.15M $30.27M
YoY Change 118.51% 22.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.63M $109.0M
Total Long-Term Liabilities $66.15M $30.27M
Total Liabilities $152.8M $143.8M
YoY Change 6.27% 107.18%
SHAREHOLDERS EQUITY
Retained Earnings $122.4M
YoY Change
Common Stock $18.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $252.0M $238.0M
YoY Change
Total Liabilities & Shareholders Equity $404.8M $381.8M
YoY Change 6.04% 44.47%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income $5.164M -$9.450M
YoY Change -154.65% -361.63%
Depreciation, Depletion And Amortization $100.0K $1.634M
YoY Change -93.88% 769.15%
Cash From Operating Activities -$126.0K $42.99M
YoY Change -100.29% 400.43%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$75.42M
YoY Change -100.0%
Cash From Investing Activities -$6.000K -$75.42M
YoY Change -99.99% -68042.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.411M -536.0K
YoY Change 1096.08% -89.73%
NET CHANGE
Cash From Operating Activities -126.0K 42.99M
Cash From Investing Activities -6.000K -75.42M
Cash From Financing Activities -6.411M -536.0K
Net Change In Cash -6.543M -32.96M
YoY Change -80.15% -1046.58%
FREE CASH FLOW
Cash From Operating Activities -$126.0K $42.99M
Capital Expenditures $6.000K $0.00
Free Cash Flow -$132.0K $42.99M
YoY Change -100.31% 406.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
247000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7763000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1006000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2169569 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36306
dei Entity Registrant Name
EntityRegistrantName
Eagle Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8179278
dei Entity Address Address Line1
EntityAddressAddressLine1
50 Tice Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 315
dei Entity Address City Or Town
EntityAddressCityOrTown
Woodcliff Lake
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07677
dei City Area Code
CityAreaCode
(201)
dei Local Phone Number
LocalPhoneNumber
326-5300
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
EGRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12986971 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15354000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55321000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
115140000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
72439000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
42482000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
47794000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14274000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13200000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
187250000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
188754000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1013000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1168000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
107406000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118327000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
45033000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
45033000 usd
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
30715000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
27146000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33405000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25732000 usd
CY2023Q2 us-gaap Assets
Assets
404822000 usd
CY2022Q4 us-gaap Assets
Assets
406160000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
15843000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18993000 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
62490000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
85844000 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
8297000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6250000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
86630000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
111087000 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
61896000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
56216000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4256000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5297000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
152782000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
172600000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17647390 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17569375 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
18000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
373831000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
366265000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1112000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1112000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
122418000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
111504000 usd
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4552730 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4552730 shares
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
243115000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
243115000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
252040000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
233560000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
404822000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
406160000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
64646000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
74136000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
130951000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
190010000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16858000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
21171000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
34158000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
46347000 usd
CY2023Q2 us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2022Q2 us-gaap Royalty Expense
RoyaltyExpense
2493000 usd
us-gaap Royalty Expense
RoyaltyExpense
0 usd
us-gaap Royalty Expense
RoyaltyExpense
5072000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9833000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11437000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19105000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17545000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27651000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36832000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55611000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59014000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
54342000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
71933000 usd
us-gaap Costs And Expenses
CostsAndExpenses
108874000 usd
us-gaap Costs And Expenses
CostsAndExpenses
127978000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
10304000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2203000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
22077000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
62032000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
195000 usd
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
244000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
407000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
398000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
1448000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
552000 usd
us-gaap Interest Expense
InterestExpense
2964000 usd
us-gaap Interest Expense
InterestExpense
918000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9720000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8071000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2548000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10240000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9298000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5868000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19529000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51792000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4134000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3582000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8615000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17184000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9450000 usd
us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.71
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.67
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13090852 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12836116 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13075090 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12773727 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13154599 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12836116 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13151107 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12951788 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
5164000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9450000 usd
us-gaap Net Income Loss
NetIncomeLoss
10914000 usd
us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
92000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
604000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1771000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1771000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1863000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2375000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5164000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7587000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
10914000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
36983000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
242845000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4192000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-147000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-14000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
5164000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
252040000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
215960000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4500000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1500000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
23645000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-36000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1863000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9450000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
237982000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
233560000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8831000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-147000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1118000 usd
us-gaap Net Income Loss
NetIncomeLoss
10914000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
252040000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
176453000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8795000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1500000 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
23645000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1341000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
8053000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2375000 usd
us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
237982000 usd
us-gaap Net Income Loss
NetIncomeLoss
10914000 usd
us-gaap Net Income Loss
NetIncomeLoss
34608000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-3967000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-4445000 usd
us-gaap Depreciation
Depreciation
219000 usd
us-gaap Depreciation
Depreciation
345000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
648000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
593000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10921000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2197000 usd
egrx Amortization Of Inventory Step Up
AmortizationOfInventoryStepUp
736000 usd
egrx Amortization Of Inventory Step Up
AmortizationOfInventoryStepUp
0 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-193000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3230000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8831000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8795000 usd
egrx Debt Securities Available For Sale Credit Loss Expense Reversal
DebtSecuritiesAvailableForSaleCreditLossExpenseReversal
0 usd
egrx Debt Securities Available For Sale Credit Loss Expense Reversal
DebtSecuritiesAvailableForSaleCreditLossExpenseReversal
62000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
226000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
236000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
77000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-620000 usd
egrx Accretion Income
AccretionIncome
0 usd
egrx Accretion Income
AccretionIncome
91000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1281000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
42701000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
44312000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4576000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8862000 usd
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
1074000 usd
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
6000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3150000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2931000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-19178000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
29006000 usd
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
755000 usd
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-193000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33638000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
26381000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
75416000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
12500000 usd
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
168000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12564000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75584000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1500000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
20000000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1265000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1341000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2500000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4000000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
8053000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6235000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-11894000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39967000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61097000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55321000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97659000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15354000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36562000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
19357000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
10570000 usd
us-gaap Interest Paid Net
InterestPaidNet
2859000 usd
us-gaap Interest Paid Net
InterestPaidNet
525000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation and Other Company Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting quarterly information. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2022 was derived from audited financial statements, but certain information and footnote disclosures normally included in our annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the results for the year ending December 31, 2023 or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 23, 2023 (the "Annual Report"). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eagle Pharmaceuticals, Inc. (the "Company", "Eagle", or "we") is an integrated pharmaceutical company focused on finding ways to help medicines do more for patients. We and our collaborators have the capabilities to take a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. Our business model applies our scientific expertise, proprietary research-based insights and marketplace proficiency to identify challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. By focusing on patients' unmet needs, we strive to provide healthcare professionals with urgently needed treatment solutions that are designed to improve patient care and outcomes and create near- and long-term value for our stakeholders, including patients and healthcare providers and our employees, marketing partners, collaborators and investors. Our science-based business model has a proven track record with the U.S. Food and Drug Administration ("FDA") approval and commercial launches of six products: PEMFEXY® (pemetrexed for injection), Ryanodex® (dantrolene sodium) ("Ryanodex"), bendamustine ready-to-dilute ("RTD") 500ml solution ("Belrapzo"), and rapidly infused bendamustine RTD ("Bendeka"), bendamustine ready-to-dilute and rapidly infused RTD in Japan (“Treakisym”), and vasopressin (now discontinued), an A-rated generic alternative to Vasostrict®. Through our acquisition of Acacia in June 2022, we added two FDA approved products with patent protection, BARHEMSYS® (amisulpride for injection) ("Barhemsys") and BYFAVO® (remimazolam for injection) ("Byfavo").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products through marketing partners and/or our internal direct sales force. We market PEMFEXY, Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. ("Teva") markets Bendeka through its subsidiary Cephalon, Inc.</span></div>Barhemsys and Byfavo are marketed to hospitals in the acute care space through our internal direct sales force. SymBio Pharmaceuticals Limited ("SymBio") markets Treakisym, a RTD product, in Japan.
egrx Number Of Products Launched
NumberOfProductsLaunched
6 product
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed consolidated financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements including disclosure of gross to net estimates as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and also require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertai</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n. As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying amount of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates, and any such differences may be material to our condensed consolidated financial statements.</span></div>
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2752708 shares
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
11281000 usd
CY2023Q2 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
8125000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
47567000 usd
CY2022Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
8125000 usd
CY2022Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Obligations
FairValueLiabilitiesMeasuredOnRecurringBasisObligations
4063000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2576314 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2603658 shares
CY2023Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
4400000 usd
CY2022Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1800000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
8100000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3400000 usd
CY2023Q2 egrx Revenue From Contract With Customer Wholesaler Discount
RevenueFromContractWithCustomerWholesalerDiscount
0.02
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5164000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5164000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9450000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9450000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
10914000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
10914000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
34608000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
34608000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13090852 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12836116 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13075090 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12773727 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
63747 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
76017 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
178061 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13154599 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12836116 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13151107 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12951788 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.71
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.67
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7834000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7769000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6821000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6601000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1013000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1168000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
12836000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
12348000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
9829000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
14064000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
19817000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21382000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
42482000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
47794000 usd
CY2023Q2 us-gaap Prepaid Taxes
PrepaidTaxes
2110000 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
90000 usd
CY2023Q2 egrx Prepaid Fda User Fee And Advances To Clinical Research Organizations
PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations
762000 usd
CY2022Q4 egrx Prepaid Fda User Fee And Advances To Clinical Research Organizations
PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations
3022000 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1385000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
258000 usd
CY2023Q2 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
4947000 usd
CY2022Q4 egrx Advances To Commercial Manufacturers
AdvancesToCommercialManufacturers
5464000 usd
CY2023Q2 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
106000 usd
CY2022Q4 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
106000 usd
CY2023Q2 egrx Pass Through Receivables
PassThroughReceivables
1144000 usd
CY2022Q4 egrx Pass Through Receivables
PassThroughReceivables
1001000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
3820000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3259000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14274000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13200000 usd
CY2023Q2 egrx Accrued Product Sales Reserves Current
AccruedProductSalesReservesCurrent
41345000 usd
CY2022Q4 egrx Accrued Product Sales Reserves Current
AccruedProductSalesReservesCurrent
33000000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1158000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5182000 usd
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
6446000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7205000 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4774000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5293000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2251000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5541000 usd
CY2023Q2 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
2022000 usd
CY2022Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1549000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1422000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1534000 usd
CY2023Q2 egrx Inventory Received But Not Invoiced
InventoryReceivedButNotInvoiced
2456000 usd
CY2022Q4 egrx Inventory Received But Not Invoiced
InventoryReceivedButNotInvoiced
6779000 usd
CY2023Q2 us-gaap Nonfinancial Liabilities Fair Value Disclosure
NonfinancialLiabilitiesFairValueDisclosure
0 usd
CY2022Q4 us-gaap Nonfinancial Liabilities Fair Value Disclosure
NonfinancialLiabilitiesFairValueDisclosure
4063000 usd
CY2023Q2 egrx Royalty Buy Down Payable
RoyaltyBuyDownPayable
0 usd
CY2022Q4 egrx Royalty Buy Down Payable
RoyaltyBuyDownPayable
15000000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
616000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
698000 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
62490000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
85844000 usd
CY2023Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y8M12D
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Operating Lease Cost
OperatingLeaseCost
845000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1507000 usd
us-gaap Lease Cost
LeaseCost
845000 usd
CY2022 us-gaap Lease Cost
LeaseCost
1507000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
845000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1507000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1422000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
839000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2261000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
134783000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
27377000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
107406000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
134783000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16456000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
118327000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5400000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10900000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2200000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
11034000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
19780000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
13917000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
11615000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
11615000 usd
CY2023Q2 egrx Finite Lived Intangible Assets Expected Amortization After Year Four
FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour
39445000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
107406000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2814878 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
91700 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
62321 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
40044 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2804213 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2425833 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
116268 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26672 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
44674 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2470755 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0349
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0423
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0331
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4431
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4688
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2023Q2 egrx Number Of Share Of Common Stock Holder Has A Right To
NumberOfShareOfCommonStockHolderHasARightTo
1 commonstock
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4192000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4500000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8831000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8795000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4192000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4500000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8831000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8795000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2374000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
839000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1122000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
413000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q2 egrx Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
0 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
71250000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
57500000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q2 egrx Long Term Debt Maturity After Year Three
LongTermDebtMaturityAfterYearThree
0 usd
CY2023Q2 us-gaap Purchase Obligation
PurchaseObligation
97430000 usd
CY2023Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
97430000 usd
CY2023Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
0 usd
CY2023Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 usd
CY2023Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 usd
CY2023Q2 egrx Purchase Obligation To Be Paid After Year Three
PurchaseObligationToBePaidAfterYearThree
0 usd
CY2023Q2 egrx Obligation
Obligation
171054000 usd
CY2023Q2 egrx Obligation To Be Paid Remainder Of Fiscal Year
ObligationToBePaidRemainderOfFiscalYear
102019000 usd
CY2023Q2 egrx Obligation To Be Paid Year One
ObligationToBePaidYearOne
11122000 usd
CY2023Q2 egrx Obligation To Be Paid Year Two
ObligationToBePaidYearTwo
57913000 usd
CY2023Q2 egrx Obligation To Be Paid Year Three
ObligationToBePaidYearThree
0 usd
CY2023Q2 egrx Obligation To Be Paid After Year Three
ObligationToBePaidAfterYearThree
0 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
400000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
400000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
800000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
800000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2400000 usd
us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
8300000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
10000000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
57500000 usd
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
71250000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4134000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3582000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8615000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17184000 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.44
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.61
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.44
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.33
egrx Number Of Tax Jurisdictions Currently Auditing The Company
NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany
3 jurisdiction
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
12500000 usd

Files In Submission

Name View Source Status
0000827871-23-000021-index-headers.html Edgar Link pending
0000827871-23-000021-index.html Edgar Link pending
0000827871-23-000021.txt Edgar Link pending
0000827871-23-000021-xbrl.zip Edgar Link pending
egrx-20230630.htm Edgar Link pending
egrx-20230630.xsd Edgar Link pending
exhibit311q22023.htm Edgar Link pending
exhibit312q22023.htm Edgar Link pending
exhibit321q22023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
egrx-20230630_def.xml Edgar Link unprocessable
egrx-20230630_lab.xml Edgar Link unprocessable
egrx-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
egrx-20230630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
egrx-20230630_cal.xml Edgar Link unprocessable